Qiming Venture Partners and Executive Director Mao Shuo Named to TMTpost's 2025 H1 Pioneer Rankings
The venture capital world is flourishing in a more diverse and dynamic direction.
Recently, TMTpost released its 2025 H1 Pioneer Rankings and Young Venture Capitalist lists.
Qiming Venture Partners was named to the Top 20 Pioneer VC Firms for Investment, Top 20 Pioneer VC Firms for Exits, Top 20 Pioneer Post-Investment Management, Top 20 Pioneer Investors in AI Agents (Vertical Applications), Top 20 Pioneer Investors in Embodied Artificial Intelligence/Robotics, Top 20 Pioneer Investors in Healthcare, and Top 10 Pioneer Investors in Consumer. Mao Shuo, Executive Director at Qiming Venture Partners, was named a 2025 H1 Young Venture Capitalist.
Qiming Venture Partners
Named to
Top 20 Pioneer VC Firms for Investment
Top 20 Pioneer VC Firms for Exits
Top 20 Pioneer Post-Investment Management
Top 20 Pioneer Investors in AI Agents (Vertical Applications)
Top 20 Pioneer Investors in Embodied Artificial Intelligence/Robotics
Top 20 Pioneer Investors in Healthcare
Top 10 Pioneer Investors in Consumer
Mao Shuo, Executive Director at Qiming Venture Partners
Named
2025 H1 Young Venture Capitalist
- 2025 H1 Pioneer Rankings
TMTpost Venture Capital collected data from 124 investment firms across four dimensions — fundraising, investment, portfolio management, and exits — conducted multi-layer verification, and ultimately published this series of rankings.
- 2025 H1 Young Venture Capitalists
This selection focuses on young investors in the primary market who maintain high frequency and precision in deal-making, and demonstrate the strongest conviction.
TMTpost noted that China's venture capital ecosystem is undergoing profound changes, with the VC world developing toward a more diverse and vibrant direction. In terms of investment sectors, both the total number of deals and total capital deployed in AI application areas are rising.
Source | TMTpost
Past Coverage
Qiming Stars | Four Qiming Venture Partners Portfolio Companies Named to Cyzone 2024 Notable Hard Tech Innovators 50 Qiming Honors | Qiming Venture Partners' Duane Kuang, William Hu, and Alex Zhou Named to PEDaily 2025 Top 100 Investors Qiming Stars | Multiple Qiming Venture Partners Portfolio Companies Appear at World Robot Conference 2025
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), Sinocelltech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.